PDC*line Pharma raises €4 million ($4.24M) in a first round and appoints Eric Halioua as president and CEO

Three Belgian investment funds and several specialized international business angels have participated in this round, which will allow the company’s cancer immunotherapy technology to reach the clinical proof of concept phase.

Liège, Belgium, and Grenoble, France, December 6, 2016 – PDC*line Pharma, a company developing a new immuno-oncology platform, today announces a first funding round of €4M ($4.24M), including €2.6M ($2.76M) in capital and €1.4M ($1.48M) in bank loans, grants and recoverable advances. Eric Halioua, serial entrepreneur and manager with a solid biotechnology and cell therapy background, has joined the company as CEO and president of the board of directors. 161206-pdc_line-fundraising-en